Search research articles
Contact Us
Filters
Showing results (411-420 of 438) with videos related to
Page
of 44
Sort By:
Lancet (London, England)
|
June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Luis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 25, 2019
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts
Paul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Cancer Cell
|
February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
Barzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 8, 2019
Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]
Paul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Helena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2017
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn, David R Spigel, Everett E Vokes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 5, 2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Clinical Lung Cancer
|
March 23, 2023
The EU-funded I<sup>3</sup>LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Arsela Prelaj, Monica Ganzinelli, Francesco Trovo', et al.
Page
of 44
Search research articles
Search
Showing results (411-420 of 438) with videos related to
Sort By:
Page
of 44
Lancet (London, England)
|
June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Luis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 25, 2019
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts
Paul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Cancer Cell
|
February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
Barzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 8, 2019
Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]
Paul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Helena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2017
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn, David R Spigel, Everett E Vokes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 5, 2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Clinical Lung Cancer
|
March 23, 2023
The EU-funded I<sup>3</sup>LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Arsela Prelaj, Monica Ganzinelli, Francesco Trovo', et al.
Page
of 44